PMID- 33716063
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20220716
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 274
DP  - 2021 Jun 1
TI  - Repurposing metformin to treat age-related neurodegenerative disorders and 
      ischemic stroke.
PG  - 119343
LID - S0024-3205(21)00328-3 [pii]
LID - 10.1016/j.lfs.2021.119343 [doi]
AB  - Aging is a risk factor for major central nervous system (CNS) disorders. More 
      specifically, aging can be inked to neurodegenerative diseases (NDs) because of 
      its deteriorating impact on neurovascular unit (NVU). Metformin, a first line 
      FDA-approved anti-diabetic drug, has gained increasing interest among researchers 
      for its role in improving aging-related neurodegenerative disorders. 
      Additionally, numerous studies have illustrated metformin's role in ischemic 
      stroke, a cerebrovascular disorder in which the NVU becomes dysfunctional which 
      can lead to permanent life-threatening disabilities. Considering metformin's 
      beneficial preclinical actions on various disorders, and the drug's role in 
      alleviating severity of these conditions through involvement in commonly 
      characterized cellular pathways, we discuss the potential of metformin as a 
      suitable drug candidate for repurposing in CNS disorders.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Sharma, Sejal
AU  - Sharma S
AD  - Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas 
      Tech University Health Sciences Center (TTUHSC), Amarillo, TX, USA.
FAU - Nozohouri, Saeideh
AU  - Nozohouri S
AD  - Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas 
      Tech University Health Sciences Center (TTUHSC), Amarillo, TX, USA.
FAU - Vaidya, Bhuvaneshwar
AU  - Vaidya B
AD  - Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas 
      Tech University Health Sciences Center (TTUHSC), Amarillo, TX, USA.
FAU - Abbruscato, Thomas
AU  - Abbruscato T
AD  - Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas 
      Tech University Health Sciences Center (TTUHSC), Amarillo, TX, USA. Electronic 
      address: thomas.abbruscato@ttuhsc.edu.
LA  - eng
GR  - R01 DA029121/DA/NIDA NIH HHS/United States
GR  - R01 NS117906/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20210311
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aging/*drug effects/pathology
MH  - Animals
MH  - Brain Ischemia/*drug therapy/pathology
MH  - Drug Repositioning/*methods
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Metformin/*therapeutic use
MH  - Neurodegenerative Diseases/*drug therapy/pathology
MH  - Stroke/*drug therapy/pathology
PMC - PMC8996678
MID - NIHMS1683878
OTO - NOTNLM
OT  - Anti- aging
OT  - Diabetes
OT  - Electronic cigarette vaping
OT  - Ischemic stroke
OT  - Metformin
OT  - Neurodegenerative diseases
OT  - Tobacco smoking
COIS- Declaration of interest: The authors declare that they have no known competing 
      for financial interests or personal relationships that could have appeared to 
      influence the work reported in this paper.
EDAT- 2021/03/16 06:00
MHDA- 2021/04/13 06:00
PMCR- 2022/06/01
CRDT- 2021/03/15 06:07
PHST- 2020/12/23 00:00 [received]
PHST- 2021/02/22 00:00 [revised]
PHST- 2021/03/03 00:00 [accepted]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2021/03/15 06:07 [entrez]
PHST- 2022/06/01 00:00 [pmc-release]
AID - S0024-3205(21)00328-3 [pii]
AID - 10.1016/j.lfs.2021.119343 [doi]
PST - ppublish
SO  - Life Sci. 2021 Jun 1;274:119343. doi: 10.1016/j.lfs.2021.119343. Epub 2021 Mar 
      11.